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Objective: To investigate the expression of the kynurenine (KYN) pathway components and the prognostic role of the KYN-to-
tryptophan ratio (KTR) in a cohort of patients with clear cell renal cell carcinoma (ccRCC).
Materials and methods: The expression of KYN pathway components was investigated by tissue microarray-based immunohistochem-
istry, indirect immunoﬂuorescence, and confocal microscopy analysis in 100 ccRCC cases and 30 normal renal samples. The role of this
pathway in sustaining cancer cell proliferation, migration, and chemoresistance was evaluated. In addition, tryptophan and KYN
concentrations and their ratio were measured in serum of 195 patients with ccRCC using a sandwich enzyme-linked immunosorbent assay.
The role of KTR as a prognostic factor for ccRCC cancer-speciﬁc survival (CSS) and progression-free survival (PFS) was assessed.
Results: Tissue microarray-based immunohistochemistry and indirect immunoﬂuorescence staining showed an increased signal for KYN
pathway components in ccRCC. Kaplan-Meier curves showed signiﬁcant differences in CSS and PFS among groups of patients with high
vs. low KTR. In particular, patients with high KTR values had a 5-year survival rate of 76.9% as compared with 92.3% for subjects with low
levels (P o 0.0001). Similar ﬁndings were observed for PFS (72.8% vs. 96.8% at 5 y). At multivariate analysis, KTR was an independent
adverse prognostic factor for CSS (hazard ratio ¼ 1.24, P ¼ 0.001), and PFS (hazard ratio ¼ 1.14, P ¼ 0.001).
Conclusions: The involvement of the KYN pathway enzymes and catabolites in ccRCC occurs via both immune and nonimmune
mechanisms. Our data suggest that KTR could serve as a marker of ccRCC aggressiveness and as a prognostic factor for CSS and PFS.r
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ntributed equally to this study.1. Introduction
Renal cell carcinoma (RCC) is one among the most
common cancers in the United States, with 63,990 esti-
mated new cases, and 14,400 estimated deaths in 2017 [1].
The pathogenesis of RCC is still poorly understood,
although cigarette smoking, obesity, hypertension, diabetes,
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common risk factors [2–4]. In recent years, emerging
evidence has conﬁrmed that metabolic reprogramming is a
cancer hallmark and has shown that many genes involved in
the RCC pathogenesis play an important role in controlling
cell metabolism [5–10]. Moreover, RCC is considered an
immunogenic tumor on the basis of several observations
that demonstrated a signiﬁcant immune inﬁltrate in tumor
stroma in association with T-cell dysfunction, the incidence
of spontaneous regression, and a partial response to
immunotherapy [11]. Multi-omics analysis of gene, protein,
and metabolite expression proﬁles of biological specimens
has led to the identiﬁcation of potential biomarkers for early
diagnosis, risk assessment, and outcome prediction,
although none of these is currently recommended in clinical
practice [12–14].
Tryptophan (TRP) is an essential amino acid that is
metabolized by 3 main pathways: incorporation into pro-
teins, serotonin production, and the formation of kynurenine
(KYN) (Fig. 1A).
The conversion of TRP to KYN is mediated by 2
enzymes: indoleamine 2,3-dioxygenase (IDO1) and trypto-
phan 2,3-dioxygenase (TDO). Recently, a novel IDO1
paralogue has been discovered, named IDO2, whose role
in TRP metabolism and cancer biology remains unclear.
IDO1 expression, which is the rate-limiting enzyme for the
TRP catabolism, can be induced in response to interferon
(IFN)-gamma and tumor necrosis factor (TNF)-alpha
stimulation.Fig. 1. (A) Tryptophan (TRP) metabolism. TRP is transformed to N-formylkyn
2,3-dioxygenase (TDO). N-formylkynurenine is then degraded by formamidase t
(IFN-γ) are the most important inducers of IDO1 expression. (B) Human kidney
metabolite proﬁling by LC/MS analysis. Tryptophan was reduced, whereas kynuren
kidney tissue (normal). y-axis: metabolite relative amount. LC/MS ¼ liquid chromIn the past decade, many studies have shown that
activation of this pathway plays an important role in cancer
progression, through the action of 2 mechanisms, namely
TRP depletion and the accumulation of immunosuppressive
metabolites such as KYN [15]. In addition, a part of the
protumorigenic role of KYN seems to be mediated by its
interaction with the aryl hydrocarbon receptor (AhR) on
immune and cancer cells [16].
In this study, we investigated the expression of the KYN
pathway components in tissue specimens derived from
patients with clear cell RCC (ccRCC), and characterized
the IDO1þ circulating and tumor-inﬁltrating immune cells.
We next evaluated the serum levels of TRP, KYN, TNF-α,
and IFN-γ, and assessed the prognostic role of the KYN-to-
TRP ratio (KTR) for ccRCC cancer-speciﬁc survival (CSS)
and progression-free survival (PFS). Finally, we explored
the possibility to target KYN/AhR axis to decreased cancer
cell viability and migration, and increased sensitivity to
chemotherapy.2. Materials and methods
2.1. Metabolite extraction and chromatography/mass
spectrometry of TRP and KYN
Primary renal tumor (n ¼ 40) and nonneoplastic tissues
(n ¼ 20) were collected from 40 patients who under-
went radical or partial nephrectomy for ccRCC. All tissueurenine by indoleamine 2,3-dioxygenase 1 (IDO1), IDO2, and tryptophan
o produce kynurenine. Tumor necrosis factor-α (TNF-α), and interferon-γ
samples were obtained by nephrectomy and metabolites were extracted for
ine was signiﬁcantly increased in primary ccRCC (tumor) compared to benign
atography/mass spectrometry. (Color version of ﬁgure is available online.)
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prepared for the appropriate investigation, liquid chroma-
tography/mass spectrometry or gas chromatography/mass
spectrometry, as previously described [8].
2.2. Study population and tissue collection
Additionally, 60 primary renal tumor and 10 nonneo-
plastic tissues were collected from patients who underwent
nephrectomy for ccRCC, for a total of 100 (40 þ 60)
ccRCC cases and 30 (20 þ 10) normal renal samples.
Two pathologists conﬁrmed the presence of ccRCC in the
neoplastic tissues and excluded tumor cells in the healthy
specimens. In addition, serum samples were collected from
195 patients with ccRCC and 50 volunteers with no
evidence of malignancy. Detailed clinical and pathological
characteristics of the patients are summarized in Table 1.
Tumor staging was reassigned according to the seventh
edition of the AJCC-UICC TNM classiﬁcation. The 2016
World Health Organization and Fuhrman classiﬁcations
were used to attribute histological type and nuclear grade,
respectively. Written informed consent to take part was
given by all participants. The protocol for the research
project has been approved by the local Ethics Committee
and conforms to the provisions of the Declaration of
Helsinki in 1995.
2.3. Serum TRP, KYN, TNF-α, and IFN-γ assay methods
Serum TRP, KYN, TNF-α, and IFN-γ levels were
measured using a sandwich enzyme-linked immunosorbent
assay according to the manufacturer’s instructions.Table 1
Clinical and pathological characteristics
Variable n ¼ 195
Age, y
Median 60
95% CI 54–63
Sex
Male 130 (67%)
Female 65 (33%)
Dimensions, cm
Median 5.0
95% CI 4.7–5.5
Pathological stage
pT1a 71 (36.5%)
pT1b 40 (20.5%)
pT2 43 (22%)
pT3 41 (21%)
pNþ 32 (16.4%)
cMþ 26 (13.3%)
Fuhrman grade
G1–2 128 (65.6%)
G3–4 67 (34.3%)
Follow-up
Median, mo 43
95% CI 38–452.4. Data mining using Oncomine gene expression
microarray datasets and metabologram
IDO1, TDO, and AhR gene expressions were analyzed
using microarray gene expression datasets deposited in the
Oncomine database (https://www.oncomine.org/resource/
login.html). In addition, the TRP metabolism was explored
using the Metabologram data portal (http://sanderlab.org/
kidneyMetabProject).
2.5. Immunohistochemistry and tissue microarray
construction
High-density tissue microarrays were used for IDO1,
TDO, AhR, and CD8 immunostaining. Archived formalin-
ﬁxed parafﬁn-embedded nephrectomy tissue samples for
additional 60 primary renal tumor and 10 nonneoplastic
tissues were obtained (for a total of 100 ccRCC cases and
30 normal renal samples). Protein immunoreactivity was
scored on the extent and intensity of staining, which was
graded on an arbitrary scale ranging from 0 to 3, with 0 ¼
negative, 1 ¼ low, 2 ¼ medium, and 3 ¼ high
expression. The CD8þ inﬁltrating cells number was meas-
ured in at least 15 high power (200) ﬁelds (hpf) by 2
independent observers.
2.6. Immunoﬂuorescence and confocal laser scanning
microscopy
Parafﬁn-embedded kidney sections were double-stained
for IDO1, CD68, CD11c, NOS2, and CD163. The expres-
sion and localization of proteins was evaluated by indirect
immunoﬂuorescence and confocal microscopy analysis.
2.7. Primary cell cultures from renal tissues
Kidney epithelial tubular and neoplastic cells were
isolated from tumor and normal kidney tissue specimens
with EpCAM (CD326) Ab-conjugated magnetic microbe-
ads (Miltenyi Biotec, Bergisch Gladbach, Germany), as
previously described [17]. These cells were then charac-
terized for EpCAM, CA IX, and AhR by immunocyto-
chemistry to conﬁrm their epithelial and renal lineage, and
to evaluate the expression of KYN receptor.
2.8. Real-time polymerase chain reaction, wound healing,
and cell viability assays
Refer to Supplementary Materials and Methods section
for details.
2.9. Flow cytometry analysis
Peripheral blood mononuclear cells (PBMCs) from 10
patients with ccRCC and 4 age and sex–matched healthy
controls were isolated by gradient centrifugation with
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performed with unconjugated mouse monoclonal anti-
IDO1 antibody (Abcam). Cells were ﬁrst stained with
Pc5.5-conjugated anti-CD14 (Beckman Coulter, Pasadena,
CA) for 15 minutes at 41C. Then cells were washed, ﬁxed,
permeabilized with BD Cytoﬁx/Cytoperm Kit (BD Bio-
sciences) and incubated for 20 minutes at room temperature
with the primary antibody. Then cells were washed and
incubated with the secondary antibody AlexaFluor 488
(Molecular Probes) for other 20 minutes. Data were
obtained using a FC500 (Beckmann Coulter) ﬂow cytom-
eter and analyzed by Kaluza software. The area of positivity
was determined using an isotype-matched monoclonal
antibody. A total of 104 events for each sample were
acquired.2.10. Statistical analysis
Statistical calculations were performed with MedCalc
9.2.0.1 (MedCalc software, Mariakerke, Belgium) and
PASW 18 software (PASW 18, SPSS, Chicago, IL,
USA). Comparisons of median protein values between
different groups were evaluated by Mann-Whitney U test.
Receiver operating characteristic curve analysis was per-
formed to identify the KTR cutoff for survival stratiﬁcation.
In the CSS analysis, patients lost to follow-up, as well as
patients who died of RCC-unrelated causes, were censored.
PFS was calculated from the date of surgery to the date of
disease recurrence. Disease progression was assessed radio-
graphically (using computed tomography scan or magnetic
resonance imaging) with a surveillance schedule based on
EAU guidelines. Estimates of CSS and PFS were calculated
according to the Kaplan-Meier method and compared with
the log-rank test. Univariate and multivariate analyses were
performed using the Cox proportional hazards regression
model to identify the most signiﬁcant variables for predict-
ing CSS and PFS. A backward selection procedure wasFig. 2. Serum kynurenine (KYN) levels and kynurenine-to-tryptophan ratios (KTR
(Color version of ﬁgure is available online.)performed with removal criterion P4 0.10 based on like-
lihood ratio tests. Spearman’s test was applied to evaluate
the correlations between KTR and tumor stage/size.
A Po 0.05 was considered statistically signiﬁcant.
Additional details regarding the experimental procedures
are provided in the Supplementary Materials and Methods
section.3. Results
3.1. Serum and tissue KYN levels are increased in ccRCC
and KTR is a risk factor for ccRCC progression and
mortality
We ﬁrst analyzed 40 primary ccRCC vs. 20 normal renal
tissues using an unbiased metabolomics proﬁle (manuscript
in preparation). This initial analysis identiﬁed statistically
signiﬁcant elevations of tissue KYN (greater than 5-fold) in
ccRCC compared to normal parenchyma, in association
with reduced levels of TRP (Fig. 1B).
Next, to evaluate the association between patients’
survival and the expression levels of KYN, this metabolite
was measured in serum of an independent cohort of 195
patients with ccRCC. As the serum KTR is a generally
accepted clinical marker of IDO1 activity, this value was
calculated for between-groups comparison and to classify
the entire population by high (Z4.5) vs. low KTR (o4.5)
according to the cutoffs obtained with receiver operating
characteristic curve analysis. Serum KYN levels and KTR
were signiﬁcantly higher in patients with RCC than in
healthy subjects (Po 0.0001) (Fig. 2). Statistically signiﬁ-
cant differences resulted between KTR values and clinical
stage (Po 0.0001; Spearman correlation, rs ¼ 0.48;
Po 0.0001), tumor size (rs ¼ 0.49, Po 0.0001),
Fuhrman grade (P ¼ 0.001), lymph node involvement
(Po 0.0001), and visceral metastases (Po 0.0001)
(Fig. 3A).) were signiﬁcantly higher in patients with ccRCC than in healthy subjects.
Fig. 3. (A) KTR median values were signiﬁcantly higher in patients with advanced disease, larger tumor size, and with lymph node involvement and visceral
metastases. (B) Kaplan-Meier cancer-speciﬁc survival (CSS) and progression-free survival (PFS) curves, stratiﬁed by KTR serum levels. Patients with higher
KTR values had reduced CSS and PFS as compared to patients with lower values. (Color version of ﬁgure is available online.)
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by the KTR, are shown in Fig. 3B. After a median follow-up
of 43 months (95% CI: 38–45), 29 patients had died of
ccRCC, and 33 had disease progression. Both CSS and PFS
were signiﬁcantly decreased in patients with high KTR
(Z4.5). Univariate analysis for the predeﬁned variables
showed that pathological stage, presence of nodal and
visceral metastases, Fuhrman grade, presence of necrosis,tumor size, and high KTR were signiﬁcantly associated with
the risk of death (Table 2) and progression (Table 3).
At multivariate analysis by Cox regression modeling, patho-
logical stage, presence of nodal and visceral metastases,
Fuhrman grade, and high KTR, were independent adverse
prognostic factors for CSS (Table 2) and PFS (Table 3).
Finally, as TNF-α and IFN-γ are the most important
inducers of IDO1 expression under certain inﬂammatory
Table 2
Univariate and multivariate analyses for cancer-speciﬁc survival
Variable Category Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
T category T3 vs. T1/2 3.81 (2.72–4.66) 0.002 2.12 (1.31–2.95) 0.01
N category Nþ vs. N0 5.71 (6.22–9.35) 0.001 4.25 (2.13–5.36) 0.001
M category Mþ vs. M0 8.21 (7.41–13.61) 0.001 5.12 (2.18–9.34) 0.001
Grade G3/4 vs. G1/2 2.84 (1.13–5.61) 0.01 1.23 (1.01–2.16) 0.01
Necrosis Yes vs. no 2.15 (1.25–3.76) 0.01 – NS
Tumor size Continuous 1.22 (1.11–1.56) 0.01 – NS
KTR Continuous 1.81 (1.20–2.11) 0.001 1.24 (1.02–1.97) 0.001
HR ¼ hazard ratio; NS ¼ not signiﬁcant.
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evaluated. We found lower levels of IFN-γ and
higher levels of TNF-α in patients with ccRCC compared
with healthy subjects (Fig. 4). In addition, TNF-α serum
levels were correlated with KTR values (rs ¼ 0.73,
Po 0.001).
3.2. IDO1 and AhR expressions are increased in renal
tumor tissue
As IDO1 and TDO are the 2 rate-limiting enzymes of
KYN formation, and this catabolite acts as an endogenous
ligand for human AhR, we analyzed the transcription levels
of these proteins in ccRCC tissue samples by quantitative
real-time polymerase chain reaction. Normalized gene
expression levels for IDO1 and AhR were signiﬁcantly
higher in the ccRCC compared with the normal tissue,
whereas we did not ﬁnd signiﬁcant difference for TDO
(Supplementary Fig. S1). To conﬁrm the above ﬁndings, we
analyzed the differential expression of IDO1, TDO, and
AhR messenger RNA by data mining of the Oncomine
microarray gene expression datasets (Supplementary Tables
S1–S3). In accordance with our results, IDO1 and AhR
were signiﬁcantly up-regulated in ccRCC (P ¼ 0.002 and
P ¼ 0.001, respectively). In addition, exploration of the
Metabologram Data Portal showed an abundance of KYN
and the up-regulation of IDO1 when comparing tumors to
normal kidney tissues (Supplementary Fig S2).
Next, to visualize the location and expression of IDO1,
TDO, and AhR, we performed immunohistochemistry onTable 3
Univariate and multivariate analyses for progression-free survival
Variable Category Univariate
HR (95% CI)
T category T3 vs. T1/2 4.22 (2.53–7.47)
N category Nþ vs. N0 3.41 (1.86–7.43)
M category Mþ vs. M0 5.06 (2.35–12.47)
Grade G3/4 vs. G1/2 2.75 (1.12–6.01)
Necrosis Yes vs. no 2.05 (1.12–2.96)
Tumor size Continuous 1.78 (1.12–2.37)
KTR Continuous 1.93 (1.12–2.45)
HR ¼ hazard ratio; NS ¼ not signiﬁcant.normal and pathological tissues, using high-density tissue
microarrays (Fig. 5A and B).
Normal kidney showed weak staining for AhR, predom-
inantly localized in the renal tubule cell cytoplasm. Instead,
pathological tissue showed a stronger staining in cancer
cells, with a prevalently nuclear pattern. Similarly, IDO1
expression was very weak in normal kidney, but showed
higher levels in ccRCC. Instead, TDO expression was very
low both in cancer and normal tissue. Interestingly, the
IDO1 signal was not identiﬁed in cancer cells but it was
present in endothelial and tumor-inﬁltrating immune cells.
Therefore, to differentiate dendritic cells from macrophages,
we evaluated IDO1/CD11c and IDO1/CD68 coexpression
in neoplastic tissue (Fig. 6). Immunoﬂuorescence staining
showed only a colocalized signal for both IDO1 and CD68
in inﬁltrating cells, demonstrating that these cells were
macrophages (Fig. 6A). Next, to evaluate the macrophages
polarization status, we studied the CD68/NOS2 (M1 macro-
phages) and CD68/CD163 (M2 macrophages) coexpres-
sion. We found that both tumor-associated macrophages
(TAMs) polarization states were present in neoplastic tissue
(Fig. 7).
Finally, as KYN pathway activation plays a role in
regulating the antitumor response of the adaptive
immune system, we evaluated the presence of
CD8þ T cells in relation to tissue levels of KYN.
We observed a reduced number of CD8þ T cells in renal
cancers with higher levels of KYN compared to
ccRCC cases with lower tissue values of this metabolite
(Fig. 5C).Multivariate
P value HR (95% CI) P value
0.001 3.21 (1.31–6.87) 0.01
0.01 2.16 (1.12–6.32) 0.01
0.001 3.89 (2.06–5.22) 0.001
0.01 1.85 (1.01–2.91) 0.01
0.01 – NS
0.01 – NS
0.001 1.14 (1.02–1.85) 0.001
Fig. 4. Tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) were measured in serum of patients with ccRCC (tumor) and in controls (normal). Lower
levels of IFN-γ and higher levels of TNF-α were found in patients with ccRCC compared with healthy subjects. (Color version of ﬁgure is available online.)
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cisplatin-induced renal cancer cell death
To study the role of KYN/AhR axis in renal cancer cell
migration and chemoresistance, in vitro assays were per-
formed. In particular, the scratch wound healing assay
showed that ccRCC cells treated with CH223191, an AhR
antagonist, had decreased cell migratory characteristics
compared with normal cells (Fig. 8). Next, we evaluatedFig. 5. (A) Immunohistochemical staining of AhR, TDO2, and IDO1 proteins in
AhR and IDO1 expression in 40 patients with ccRCC for which KYN tissue level
reduced number of inﬁltrating CD8þ T cells compared to tumors with low KYN
online.)the role of AhR activation in reducing cisplatin-induced
cytotoxicity. Normal and renal cancer cells were pretreated
with CH223191. After cisplatin treatment, the death rate of
tumor cells treated with CH223191 was signiﬁcantly greater
than that of untreated cancer cells (Po 0.001, Fig. 9A and
B). MTT assay conﬁrmed these ﬁndings by demonstrating
decreased cell viability when tumor cells were pretreated
with CH223191 before cisplatin incubation (69% at 1 h and
58% at 2 h) (Fig. 9C).tissue microarrays of human ccRCC specimens. (B) Heat map summarizing
s were available. (C) ccRCC specimens with high KYN tissue levels show a
values. Original magniﬁcation 20. (Color version of ﬁgure is available
Fig. 6. Evaluation of IDO1þ tumor-inﬁltrating cells. To differentiate macrophages from dendritic cells, we evaluated IDO1/CD68 and IDO1/CD11c
coexpression in neoplastic tissue. Immunoﬂuorescence and confocal laser scanning microscopy demonstrated colocalization only for IDO1 and CD68 (A),
whereas no colocalization was found for IDO1 and CD11c (B). (Color version of ﬁgure is available online.)
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Fig. 7. To evaluate the macrophages polarization status, CD68/NOS2 (M1 macrophages—panel A) and CD68/CD163 (M2 macrophages—panel B)
coexpressions were studied. Colocalization analysis showed that both tumor-associated macrophages (TAMs) populations were present in neoplastic tissue.
(Color version of ﬁgure is available online.)
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Fig. 8. Wounded normal and tumor cell monolayers were photographed 12 and 24 hours after the mechanical scratch and the area of the wounds was
measured in 3 independent wound sites per group. When speciﬁed, the cells were exposed to 10 mM of CH223191 for 1 hour. RCC cells treated with
CH223191 had decreased cell migratory capabilities compared with untreated tumor cells. (Color version of ﬁgure is available online.)
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Flow cytometry was used to analyze the expression of
IDO1 in freshly isolated PBMCs derived from patients with
ccRCC with nonmetastatic vs. metastatic disease and
compared with healthy controls. Considering the role ofFig. 9. AhR has a role in RCC resistance to cisplatin (CDDP)-induced cyto
(tumorþCH223191þCDDP) was signiﬁcantly higher than that of unblocked cell
blocked (normal þ CH223191 þ CDDP) and unblocked (normal þ CDDP) norm
renal tumor cells were pretreated with CH223191 before cisplatin incubation C.IDO1þ TAMs in ccRCC specimens, to analyze circulating
monocytes, a gate was set around the CD14þ cells. We
found a signiﬁcant increase of circulating CD14þ/IDO1-
þ in patients with metastatic disease compared with
patients with a localized tumor, as well as with healthy
controls (Fig. 10).toxicity. (A) At 1 and 2 hours, the death rate of blocked tumor cells
s (tumor þ CDDP) (P o 0.001). (B) No difference was observed between
al cells. (C) MTT assay revealed signiﬁcantly decreased cell viability when
(Color version of ﬁgure is available online.)
Fig. 10. Circulating IDO1þ CD14þ cells evaluated using ﬂow cytometry on peripheral blood mononuclear cells. (A) A representative ﬂow-cytometric
analysis of one experiment is reported and the percentages of gated cells are shown. (B) Columns represent mean  SD of IDO1þ CD14þ cells in healthy
donors and in patients with nonmetastatic and metastatic ccRCC. SD ¼ standard deviation.
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Many studies have shown that KYN pathway dereg-
ulation has a role in cancer progression and is negatively
associated with patients’ clinical outcome [18–20].
In the present study, we found that KYN was elevated
nearly 6-fold in ccRCC tumor tissue, in association with
reduced tissue levels of TRP. Therefore, to identify
potential factors that could promote KYN accumulation in
ccRCC, we initially analyzed the expression of the KYN-
generating enzymes using quantitative real-time polymerase
chain reaction and data mining of public Oncomine micro-
array datasets [21–25]. We found that only IDO1 mRNA
was up-regulated in ccRCC, in association with the up-
regulation of AhR, the widespread mediator of KYN action
in tumor cells; these results were in accordance with a
previous study that showed the existence of a mutually
exclusive activation of IDO1 and TDO in cancer [16].
We next performed an immunohistochemical evaluation of
protein expression and found that IDO1 was expressed in
tumor endothelial cells, but especially in TAMs. The role of
IDO1 in ccRCC endothelial cells was previously explored
by Riesenberg et al. [26] who showed that tumors with a
higher IDO-positive endothelial cells rate exhibited an
increased microvascular density. TMAs are important
regulators of the complex cross-talk between immune
system and cancer cells. In agreement with recent studies
that re-evaluated the TAM phenotypes beyond the M1/M2
polarization status [27], we found that both macrophagessub-populations were present in ccRCC and contributed to
KYN production.
Opitz et al. [16] reported that KYN is an endogenous
ligand of the AhR receptor, a cytoplasmic protein that
moves into the nucleus, where it binds target genes and
promotes tumor cell migration. We found that AhR was
highly expressed in ccRCC, and its inhibition decreased
cancer cell migratory capabilities in vitro. Cytotoxic chemo-
therapy has been largely ineffective in RCC. In recent years,
an in-depth understanding of the molecular basis of ccRCC
has led to the introduction of antiangiogenic therapies for
this tumor, although these drugs yield partial responses in a
minority of patients, with no evidence of complete
responses [28,29]. Recent evidence suggested that AhR
inhibition could increase sensitivity to chemotherapeutic
drugs [30], so we hypothesized that AhR could be
implicated in ccRCC chemoresistance. To explore this
hypothesis, renal cancer cells were pretreated with
CH223191, an AhR antagonist, and then incubated with
cisplatin. Cisplatin was chosen for its broad-spectrum
anticancer activity, and its inefﬁcacy in ccRCC. After
cisplatin incubation, the cell death rate of RCC cells treated
with CH223191 was signiﬁcantly higher than that of unblocked
cancer cells, suggesting a role of the IDO1-KYN-AhR pathway
in mediating a chemoresistance mechanism in ccRCC.
As the serum KTR is a generally accepted clinical
marker of IDO1 activity, we evaluated this parameter in a
cohort of patients with ccRCC compared to healthy
individuals.
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in ccRCC prognosis, we stratiﬁed the patients’ population
according to KTR values. Kaplan-Meier curves showed
signiﬁcant differences in CSS and PFS between the patients
groups with high vs. low KTR. Patients with high values of
KTR had a 5-year survival rate of 76.9%, as compared to
92.3% for subjects with low levels (P o 0.0001). Similar
ﬁndings were observed for PFS (72.8% vs. 96.8% at 5 y).
These ﬁndings are in accordance with the results of
other studies showing that high IDO1 activity contributes
to the aggressive phenotype of different types of cancer
[18–20].
Multivariate analyses demonstrated that high values of
KTR (hazard ratio = 1.24, P = 0.001) together with pT-
stage42, Fuhrman grade Z3, and the presence of nodal
and visceral metastases, were signiﬁcantly predictive of the
risk of death. Similarly, this parameter remained an
independent prognosticator of outcome in PFS (hazard
ratio = 1.14, P = 0.001). However, it must be pointed
out that, although high values of KTR were signiﬁcantly
predictive of CSS and PFS, clinical factors such as pT-
stage, N-stage, and M-stage were still much stronger
predictors of poor outcomes than KTR.
Some studies have shown that high IDO1 activity is
associated with increased tumor cell motility and metastatic
potential. In agreement with these ﬁndings, we observed
increased values of KTR in metastatic ccRCC compared to
localized tumors. In particular, KTR values were signiﬁ-
cantly increased in patients with lymph node (P o 0.0001)
and visceral metastases (P o 0.0001).
As TNF-α and IFN-γ are the most important cytokines
involved in IDO1 expression, we evaluated the serum levels
of these proteins in serum of patients with ccRCC.
Interestingly, we found increased levels only of TNF-α,
whereas IFN-γ values were signiﬁcantly reduced in patients
with cancer. Moreover, we observed an increased number
of circulating IDO1þ monocytes in patients with advanced
disease compared with patients with localized tumors and
healthy individuals, suggesting that TNF-α could induce
IDO1 in circulating monocytes, that successively populate
tumor stroma as TAMs where they contribute to KYN
production. Furthermore, TAMs could originate from
tissue-resident macrophages arising from dedicated yolk
sac progenitors [27]. In this setting, the generation of KYN,
in association with TRP depletion, would cooperate with
the low levels of IFN-γ to impair the antitumor response of
the adaptive immune system. In fact, cytotoxic T cells were
signiﬁcantly reduced in tumors with higher tissue values of
KYN. Therefore, according to this model that connects the
metabolic deregulation with immune escape, the KYN
produced by IDO1þ TAMs would not only impair the
immunosurveillance by reducing the number of CD8þ T
cells, but also by promoting cancer cells survival, migration,
and chemoresistance through its interaction with AhR.
The main limitations of this study include the single-
center design of the report, and its retrospective nature.5. Conclusions
The involvement of the KYN pathway enzymes and
catabolites in cancer occurs via both immune and non-
immune mechanisms. In this study, we provide a detailed
description of KYN pathway expression in ccRCC and
discuss some clinical implications. In particular, we found
that KTR could serve as a marker of ccRCC aggressiveness
and as a prognostic factor for CSS and PFS. The inactiva-
tion of this pathway may serve as a novel therapeutic target.Appendix A. Supporting information
Supplementary data associated with this article can be
found in the online version at http://dx.doi.org/10.1016/j.
urolonc.2017.02.011.References
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